About
Scientific Advisory Board
Craig A. Smith, Ph.D., Founder, VLST Scientific Fellow and
Chairman of the Scientific Advisory Board

Craig A. Smith, Ph.D. is co-founder, VLST Scientific Fellow and Chairman of the Scientific Advisory Board of VLST Corp. Prior to co-founding VLST, Dr. Smith's research accomplishments at Immunex include having cloned a receptor for TNF and, working with colleague Dr. Ray Goodwin, engineered a novel, soluble recombinant form (later termed Enbrel) for use in treating autoimmune diseases such as rheumatoid arthritis. For this discovery and invention, both Dr. Smith and Dr. Goodwin shared the Scientific Achievement Award from the National Arthritis Foundation, the PhRMA Discoverers Award and the IPO National Inventor of the Year (2001). He has published more than 100 scientific articles and is a named inventor on 20 patents.

Dr. Smith also initiated and led a research program that discovered novel superfamilies of TNF-related gene products, which collectively help orchestrate fundamental immune processes, several of which are in clinical trials for cancer and autoimmune disorders. Long interested in virology, Dr. Smith is generally credited with establishing the molecular nature of virulency genes in eukaryotic viruses which productively infect humans and animals: many of which encode proteins that modulate the host immune response to viral advantage by targeting crucial genes of the human immune system. The research program put in place to exploit this observation led to the co-founding of VLST. Dr. Smith received his B.S. in Molecular Biology from the University of Wisconsin, Madison and his Ph.D. in Molecular Biology from the Molecular Biology Institute at the University of California, Los Angeles.

David Cosman, Ph.D.
David Cosman, Ph.D. has 23 years of biotechnology research experience at Immunex and Amgen where he held the positions of Vice President of Molecular Biology and Senior Investigator (Immunex) and Distinguished Fellow and Research Director (Amgen). He has published more than 120 refereed scientific papers and reviews, mostly in the fields of cytokine receptor biology, leukocyte regulatory receptors and human cytomegalovirus subversion of the immune system. Dr. Cosman has served on the Scientific Advisory Boards of the Keystone Symposia and Amgen Ventures. He obtained a B.A. in Natural Sciences from Cambridge University, a Ph.D. in Microbiology from Pennsylvania State University and post-doctoral training as a Fogerty Fellow at the National Cancer Institute before joining Immunex in 1983.

Geoff Duyk, M.D., Ph.D.
Dr. Geoff Duyk currently serves as Managing Director at TPG Growth. Prior to joining TPG Growth in 2004, Dr. Geoff Duyk served on the Board of Directors and was President of Research & Development at Exelixis where he led a 550+ person group focused on the discovery and development of small molecule therapeutics. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals. As Vice President of Genomics at Millennium, Dr. Duyk was responsible for building and leading the informatics, automation, DNA sequencing and genotyping groups as well as the mouse and human genetics group. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the human genome project.

Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from the Howard Hughes Medical Institute.

Dr. Duyk serves on the Board of Directors of Avidia, Macrogenics, Open Biosystems, Aerie and Replidyne. He also serves on the Scientific Advisory Boards of the (NIH) Counsel of NHGRI DNA Sequencing Advisory Panel, Chair of the KOMP (Global Mouse TKO project), ESC (Expressed Sequenced Consortium), Co-Chair Advisory Panel Cancer Genome Project, Program in Genomics Applications (NHBLI); the Bioethics Advisory Group at Case Western Reserve University; Spinal Muscular Atrophy Foundation; Jackson Laboratories - Bar Harbor Maine; Molecular Sciences Institute (UCB) and WIL Laboratories.

Adam P. Geballe, M.D.
Adam Geballe, M.D. is a Professor of Medicine at the University of Washington in the Division of Allergy and Infectious Diseases and is an Adjunct Professor of Microbiology.  Dr. Geballe is also a member of the Fred Hutchinson Cancer Research Center and a Research Affiliate in the Center on Human Development and Disability.  Dr. Geballe has expertise and research interest in translational regulation of viral and cellular gene expression.  Dr. Geballe obtained his MD at Duke University. Dr. Geballe previously sat on the editorial board of Journal of Infectious Diseases as well as an ad hoc reviewer for over 15 scientific journals.

Raymond Goodwin, Ph.D.
Ray Goodwin, Ph.D. obtained his Ph.D. in Biochemistry from the University of California at Riverside and held positions at Case Western Reserve University, Genentech and Immunex/Amgen Corporations prior to joining VLST Corp at its founding as a Scientist.  At Immunex, Dr. Goodwin was the co‑inventor and co-developer of Enbrel with Company founder Craig Smith.  He has published more than 75 scientific articles and book chapters, received more than 15 patents, is a Phi Betta Kappa and has received the PhRMA Discoverers Award and the IPO National Inventor of the Year (2001) for his involvement as co-inventor of Enbrel.

Peter Kiener, Ph.D.
Peter Kiener, Ph.D. is the senior vice president, research, for MedImmune, Inc. with oversight of the company’s global research activities. He joined MedImmune, Inc. in 2001 and was named vice president, research, in 2003. His scientific areas of expertise include immunology, cellular and molecular biology, biochemistry and high-throughput screening assays, and in vivo studies.

Prior to joining MedImmune, Dr. Kiener spent 18 years with Bristol-Myers Squibb’s (BMS) Pharmaceutical Research Division, finally holding the position of director, immunology, inflammation, pulmonary and oncology drug discovery at the BMS facility in Princeton, NJ.

Before his employment at Bristol-Myers, Dr. Kiener previously served as assistant professor at the University of North Texas/Texas College of Osteopathic Medicine’s Department of Anatomy; as a research associate at the Department of Biochemistry, University of Massachusetts (Amherst); and, as a postdoctoral research assistant, Medical Research Council, Sir William Dunn School of Pathology, University of Oxford.

Dr. Kiener holds a B.S. degree with honors in chemistry from Lancaster University, Lancaster, UK, and a doctorate of philosophy in biochemistry from the Sir William Dunn School of Pathology, Oxford University, Oxford, UK.

Dhavalkumar D. Patel, M.D., Ph.D.
Dhaval Patel, M.D., Ph.D., is a physician/scientist who received his medical and graduate (Microbiology and Immunology) degrees from Duke University, Durham, NC.  His graduate studies were in poxvirus biology.  He completed a residency in Internal Medicine and fellowships in Rheumatology and Allergy/Immunology at Duke and was the Chief of the Division of Allergy and Immunology at Duke prior to moving to the University of North Carolina to lead the Thurston Arthritis Research Center and the Division of Rheumatology, Allergy and Immunology.  Dr. Patel is a Fellow of the American College of Rheumatology and the American Academy of Allergy, Asthma, and Immunology.  In addition to being a reviewer for more than 15 journals, Dr. Patel has served on the editorial boards for The Journal of Immunology, Arthritis & Rheumatism, and Arthritis Research and Therapy.

David J. Pickup, Ph.D.
David Pickup, Ph.D. is an Associate Professor of Molecular Genetics and Microbiology at Duke University. A nationally known expert in the pathogenesis of orthopoxvirus infections (smallpox, monkeypox, vaccinia virus infections), he works to understand how these viruses cause disease, and how to use this knowledge to make better vaccines against this group of viral diseases. Dr. Pickup obtained his Ph.D. in Virology at the National Institute for Medical Research in London. Dr. Pickup currently is an Associate Editor for Virology and was previously an Associate Editor for Protein Expression and Purification.

Edward Scolnick, M.D.
Edward Scolnick, M.D. was President of Merck Research Labs from 1985-2002. Under his direction, Merck introduced breakthrough medications for the treatment of HIV, osteoporosis, heart disease, osteoarthritis and pain. Prior to this position, Dr. Scolnick was Chief of the Laboratory of Tumor Virus Genetics at the National Cancer Institute. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine. Dr. Scolnick received his B.A. and M.D. from Harvard University.  He is currently Executive Advisor to MPM Capital and an Associate Member of the Broad Institute at MIT and Harvard.